FDA Brief

Warning letters Drugs

FDA warning letter to

Iso-Tex Diagnostics, Inc.

High riskIssued Jul 20, 2023Posted Aug 1, 2023Division of Pharmaceutical Quality Operations II

FDA warns Iso-Tex Diagnostics over manufacturing violations that risk contamination of sterile radiopharmaceutical drugs.

What happened

FDA inspected Iso-Tex's drug manufacturing facility in Alvin, TX, from January 30 to February 10, 2023. FDA found violations of current good manufacturing practice (CGMP), the rules for drug manufacturing, including cleanroom design and environmental monitoring failures, poor aseptic gowning and airflow practices during filling, and inadequate laboratory controls. FDA said these problems significantly increased contamination risk and noted similar violations in prior inspections and a 2010 warning letter.

What FDA found

  1. Cleanrooms were not properly designed or maintained: a door could not fully close, particles hung from HEPA filters, light fixtures and electrical sockets were not sealed, and pressure and humidity excursions were not investigated.

    21 CFR 211.42(a); 21 CFR 211.42(c)(10)(iv) & (v)
  2. Personnel entered the ISO 5 filling area with exposed skin and hair, failed to disinfect gloves, gowned poorly, and equipment blocked unidirectional airflow during filling of Volumex I-131.

    21 CFR 211.113(b)
  3. Laboratory reagents were inadequately labeled and expired testing materials were used, which may affect testing used to release drug products.

    21 CFR 211.160(b)

What FDA wants

FDA tells Iso-Tex to correct the violations promptly and respond in writing within 15 working days with risk assessments, remediation plans, corrective and preventive action (CAPA), and independent assessments; FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • patients receiving sterile radiopharmaceutical injections
  • hospitals and nuclear medicine departments that use radiopharmaceuticals
  • drug manufacturers and suppliers relying on Iso-Tex products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  4. Hanlim Pharm Co., Ltd.

    FDA warned Hanlim Pharm over serious sterile manufacturing violations, including poor aseptic practices and airflow problems, at its South Korea plant.

    High risk